Results
eNauka >
Rezultati >
A randomized, double-blind, multinational phase III study to assess the efficacy and safety of lazertinib versus gefitinib in the first-line treatment of patients with EGFR mutation (EGFRm), advanced NSCLC (LASER301; NCT04248829)
| Naziv: | A randomized, double-blind, multinational phase III study to assess the efficacy and safety of lazertinib versus gefitinib in the first-line treatment of patients with EGFR mutation (EGFRm), advanced NSCLC (LASER301; NCT04248829) | Autori  : | Cho, BC; ...; Zaric, Bojan   |
Godina: | 2022 | Publikacija: | ANNALS OF ONCOLOGY | ISSN: | 0923-7534 Annals of Oncology Pretraži identifikator |
Tip rezultata: | Konferencijski rad | Kolacija: | vol. 33 br. Suppl 9 str. S1560-S1560 | DOI: | 10.1016/j.annonc.2022.10.349 | WoS-ID: | 000897943700317 | URI: | https://enauka.gov.rs/handle/123456789/828158 | Projekat: | Yuhan Corporation | Izvor metapodataka: | (Preuzeto iz Nasi u WoS) | Napomena: | ESMO Asia Congress, Singapore, SINGAPORE, DEC 02-04, 2022 | M-kategorija: | Mp kategorija će biti prikazana naknadno. |
Items in eNauka are protected by copyright, with all rights reserved, unless otherwise indicated.